🎗️ OncologyInjection (IV)
Carvykti
Ciltacabtagene Autoleucel
BCMA-directed CAR T-cell therapy for relapsed/refractory multiple myeloma after prior lines of therapy.
Form
Injection (IV)
Uses
1
Side effects
5
Category
Oncology
01
What is Carvykti used for?
- Relapsed/refractory multiple myeloma
02
Ciltacabtagene Autoleucel side effects
Common side effects of Ciltacabtagene Autoleucel include:
Cytokine release syndrome
Neurotoxicity (ICANS)
Infections
Cytopenias
Movement disorders
CommonModerateLess common
03
Ciltacabtagene Autoleucel warnings & precautions
- Black box: CRS, neurotoxicity, HLH/MAS, prolonged cytopenias, and secondary T-cell malignancies
- REMS required
- Only at certified centers
Loading FDA data…
04
Frequently asked questions
05
Related medications
Share
Share this drug info.
Help friends and family understand Carvykti in plain language.
Disclaimer: This information is sourced from the FDA openFDA database and is provided for educational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult your physician or pharmacist before starting or changing medication.